ClinicalTrials.gg
RecruitingNCT05305066SUPRAUpdated Feb 3, 2026

Stand UP to Rheumatoid Arthritis (SUPRA)

An interventional study of TNFi and Anti-IL6 in Rheumatoid Arthritis, sponsored by Marie Hudson, MD. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Marie Hudson, MD · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies testing etanercept in Arthritis, Rheumatoid — 4 open to participants now, 5 under way, 1 of them phase 3. Etanercept · Arthritis, Rheumatoid.

Planned enrollment
51st of 69
75 · median 144
Started
2023
the only one that year
No phase
2 of 69
1 open now
Registered
68th of 69
by date

Among the 69 studies testing etanercept in Arthritis, Rheumatoid, this one is the 51st largest by planned enrollment, is the only one that started in 2023, is one of 2 with no phase, and was the 68th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 69 studies testing etanercept in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About etanercept

Etanercept: first FDA approval 1998 (ENBREL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing etanercept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.

Read the detailed description

Rheumatoid arthritis (RA) is a complex, chronic disease of the immune system characterized by disfiguring and disabling arthritis. It affects predominantly women (3:1 ratio with men) and has its peak onset during their most productive years (ages 30-50). RA is associated with serious morbidity (including impaired fertility and pregnancy outcomes, disability, and depression) and premature mortality (particularly from cardiovascular and infectious causes). The Arthritis Alliance of Canada estimates that the cost of RA will exceed $30 billion in Canada in 2040.

First-line treatment of RA consists of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with methotrexate considered as the gold standard. Yet, only 30% of patients will achieve adequate response to methotrexate and the majority will need additional treatment. The development of new biologic and targeted synthetic DMARDs (b/tsDMARDs) in the 20th century has transformed the treatment of RA. Anti-tumour necrosis factor (TNF)-α molecules were the first clinically successful biologic therapies for RA. Drugs targeting other signaling pathways (JAK-STAT, which work downstream of interferons), inflammatory cytokines (IL-6), as well as B cells and T cells have now also become available. Molecules with novel targets (eg. GM-CSF, CD40L) are in clinical trials.

Although hailed as 'game-changers' in patient care, the inconvenient truth is that even though nine different b/tsDMARDs are currently available to treat RA, 30% of patients will fail any particular drug. Moreover, physicians have no reliable way of predicting response and guiding treatment decisions. Clinical and genetic predictors have been the subject of intense research but these factors explain only a small portion of the observed variance in treatment response. Using the current trial-and-error approach, patients can cycle through multiple drugs before finally attaining disease control. This means months or years of suboptimal disease control and considerable losses in many domains including physical and emotional well-being, family and social networks, and occupational attainment. The lack of a personalized approach is particularly detrimental in RA because there is a narrow ''window of opportunity'' in the first 3-6 months of onset to control disease and optimize long term outcomes. In addition, failure to personalize treatment may also result in wasted spending on ineffective drugs, that cost up to $20,000 per patient per year, and exposing patients to unnecessary risks of adverse events, in particular serious infections.

There is a critical need to 1) transform the current 'trial-and-error' treatment paradigm, 2) explore novel predictors of b/tsDMARD response in RA and, 3) harness the power of advanced analytical strategies to personalize treatment decision-making and optimize outcomes in RA. The investigators propose a multi-pronged solution that combines innovative trial designs, multi-omics and advanced computational prediction to transform clinical care in RA.

The investigators propose to develop a new model of care and investigate new avenues, including sex and gender, diet, gut bacteria and environmental exposures, to make treatment decisions. The investigators will also use new methods of analyzing complex information. The highly talented research team has what is needed to transform the care of people living with RA.

In preparation for a full-scale study, the investigators propose this feasibility study.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
  • Pragmatic trials
  • Feasibility
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA;
  • Failure to standard conventional synthetic DMARDs and eligible for b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2).

Exclusion criteria

Exclusion Criteria:

  • Prior b/tsDMARDs for Sub-study 1 or prior b/tsDMARDs other than TNF inhibitors for Sub-study 2;
  • to b/tsDMARD therapy, such as active infection or untreated latent TB, current , severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy/lactation;
  • Overlap with another inflammatory disease requiring specific therapy, such as lupus nephritis;
  • Unable to provide consent or complete forms (alone or with assistance) in English or French
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Sub-study 1 TNFi

    TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein), adalimumab (monoclonal antibody), golimumab (monoclonal antibody), or certolizumab (pegylated fragment of a monoclonal antibody)

    Drug: TNFi

  • Active comparator
    Sub-study 1 Anti-IL6

    Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab

    Drug: Anti-IL6

  • Active comparator
    Sub-study 2 Anti-IL6

    Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab

    Drug: Anti-IL6

  • Active comparator
    Sub-study 2 JAKi

    JAKi - tofacitinib (JAK1/3 inhibitor), baricitinib (JAK 1/2 inhibitor) or upadacitinib (JAK1 inhibitor)

    Drug: JAKi

Interventions

  • DrugEtanerceptStudies of EtanerceptEtanercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.

    Also known as: Etanercept, Adalimumab, Golimumab, Certolizumab

  • DrugTocilizumabStudies of TocilizumabTocilizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)

    Also known as: Tocilizumab, Sarilumab

  • DrugTofacitinibStudies of TofacitinibTofacitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)

    Also known as: Tofacitinib, Upadacitinib, Baricitinib

06

What researchers measure

Primary outcomes

  1. Rate of recruitment at two RA referral centers over 12 months

    Feasibility outcome

    Time frame: 12 months

  2. Prompt access to drugs

    Feasibility outcome

    Time frame: 4 weeks

  3. Proportion of participants adhering to the allocated treatment

    Feasibility outcome

    Time frame: 24 months

  4. Proportion of eligible patients who are invited to participate by their physician

    Physician acceptability outcome

    Time frame: 12 months

  5. Proportion of eligible patients who accept to participate

    Patient acceptability outcome

    Time frame: 12 months

  6. Proportion of patients reaching SDAI <= 3.3

    Exploratory outcome

    Time frame: 24 months

  7. Proportion of patients reaching DAS28 LDA state

    Exploratory outcome

    Time frame: 24 months

  8. Patient-reported outcomes (function, health-related quality of life, fatigue)

    Exploratory outcome

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015 May 8;350:h2147. doi: 10.1136/bmj.h2147. No abstract available. PubMed 25956159 ↗

Individual participant data

Plan to share: Yes — Participants' study information and biological samples may be shared with researchers at this institution or other institutions for genetic, immunological, and other analyses (e.g. microbiome sequencing, biomarkers analyses, etc.).

Supporting information: Study protocol

Time frame: After 2025, for 3 years

Access criteria: The sharing of these samples will be done under specific research agreements; the samples and the data will be coded and confidentiality strictly protected.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2028, 70 months after the start.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 70 months is above that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2022
First posted
Mar 31, 2022
StartActual
Feb 1, 2023
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 2030
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05305066
Lead sponsor
Marie Hudson, MD
Collaborators
McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal General Hospital, Lady Davis Institute
Responsible party
Marie Hudson, MD (Rheumatologist, Jewish General Hospital; Physician-scientist, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis - Jewish General Hospital) — Sponsor-investigator
First posted
Mar 31, 2022
Start date
Feb 1, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Feb 3, 2026

Study contacts

Marie Hudson, MD
Contact
marie.hudson@mcgill.ca
514-340-8222 ext. 23476
Marie Hudson, MD
principal investigator · Sir Mortimer B. Davis - Jewish General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etanercept · Tocilizumab · Tofacitinib

Start the discussion